Cargando…

Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis

BACKGROUND: Population attributable risk percent (PAR%) is an epidemiological tool that provides an estimate of the percent reduction in total disease burden if that disease could be entirely eliminated among a subpopulation. As such, PAR% is used to efficiently target prevention interventions. Due...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubberke, Erik R., Olsen, Margaret A., Stwalley, Dustin, Kelly, Ciarán P., Gerding, Dale N., Young-Xu, Yinong, Mahé, Cedric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747338/ https://www.ncbi.nlm.nih.gov/pubmed/26859403 http://dx.doi.org/10.1371/journal.pone.0146822

Ejemplares similares

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population
por: Olsen, Margaret A, et al.
Publicado: (2018)

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
por: Gerding, Dale N, et al.
Publicado: (2018)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Burden of Clostridium difficile on the Healthcare System
por: Dubberke, Erik R., et al.
Publicado: (2012)

Attributable Outcomes of Endemic Clostridium difficile–associated Disease in Nonsurgical Patients
por: Dubberke, Erik R., et al.
Publicado: (2008)

497. Identification of Patients at Risk of Clostridium difficile Infection for Enrollment in Vaccine Clinical Trials
por: Stevens, Vanessa, et al.
Publicado: (2018)

The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection
por: Gerding, Dale N., et al.
Publicado: (2017)

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2016)

Etiology of Infectious Diarrhea in Patients Tested for Clostridium difficile: If It Isn’t Clostridium difficile, What Is It?
por: Kwon, Jennie H, et al.
Publicado: (2017)

Risk factors for healthcare-associated Clostridium difficile infection in pediatric hematopoietic stem cell transplant recipients
por: Drew, Richard H, et al.
Publicado: (2017)

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings
por: Durham, David P., et al.
Publicado: (2016)

Clostridium difficile binary toxin CDT: Mechanism, epidemiology, and potential clinical importance
por: Gerding, Dale N, et al.
Publicado: (2014)

Non-toxigenic Clostridioides (Formerly Clostridium) difficile for Prevention of C. difficile Infection: From Bench to Bedside Back to Bench and Back to Bedside
por: Gerding, Dale N., et al.
Publicado: (2018)

Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2022)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Spore Formation and Toxin Production in Clostridium difficile Biofilms
por: Semenyuk, Ekaterina G., et al.
Publicado: (2014)

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period
por: Dubberke, Erik R., et al.
Publicado: (2017)

16. Attributable Mortality, Healthcare Costs and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2021)

Determining Mortality Rates Attributable to Clostridium difficile Infection
por: Hota, Susy S., et al.
Publicado: (2012)

Attributing Cause of Death for Patients with Clostridium difficile Infection
por: Gilca, Rodica, et al.
Publicado: (2012)

Risk factors for hospital-onset Clostridioides difficile infections before and during the severe acute respiratory syndrome coronavirus 2 pandemic
por: Kwon, Jennie H., et al.
Publicado: (2023)

976. Clostridium difficile Colonization Molecular Epidemiology and Anti-toxin Serological Responses in Healthy Infants: A Prospective Cohort Study
por: Kociolek, Larry, et al.
Publicado: (2018)

Toxin B is essential for virulence of Clostridium difficile
por: Lyras, Dena, et al.
Publicado: (2009)

Toxinotype V Clostridium difficile in Humans and Food Animals
por: Jhung, Michael A., et al.
Publicado: (2008)

ICD-9 Codes and Surveillance for Clostridium difficile–associated Disease
por: Dubberke, Erik R., et al.
Publicado: (2006)

Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
por: Soriano, Melinda M., et al.
Publicado: (2014)

492. Long-Term Outcomes of Clostridium difficile Infection Among Medicare Beneficiaries
por: Hatfield, Kelly M, et al.
Publicado: (2018)

Multihospital Outbreak of Clostridium difficile Infection, Cleveland, Ohio, USA
por: Jump, Robin L.P., et al.
Publicado: (2010)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Clostridium difficile outbreaks: prevention and treatment strategies
por: Martinez, Fernando J, et al.
Publicado: (2012)

Mortality, Hospital Costs, Payments, and Readmissions Associated With Clostridium difficile Infection Among Medicare Beneficiaries
por: Drozd, Edward M., et al.
Publicado: (2015)

A Simulation-Based Assessment of Strategies to Control Clostridium Difficile Transmission and Infection
por: Rubin, Michael A., et al.
Publicado: (2013)

The Risk Factors of Clostridium difficile Colitis in Colorectal Surgery
por: Yoo, Seung Jin
Publicado: (2010)

Depression, antidepressant medications, and risk of Clostridium difficile infection
por: Rogers, Mary A M, et al.
Publicado: (2013)

Risk Factors for Delayed Recurrence of Clostridium difficile Infection
por: Kim, Ji Won
Publicado: (2014)

Clostridium difficile Infection in Special High-Risk Populations
por: Cózar-Llistó, Alberto, et al.
Publicado: (2016)

1624 Risk Factors for Hospital-Acquired Clostridium difficile
por: Knepper, Bryan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qveko56456k2u7c3mnt0rmo9nn